Robert McDowell - MyoKardia Sr. VP of Drug Discovery
SVP
Dr. Robert Scott McDowell, Ph.D. is Senior Vice President Drug Discovery of the Company. Prior to joining us, Dr. McDowell led drug discovery at 3V Biosciences, Inc. from October 2008 to July 2012, advancing the companys lead program into development. Prior to 3V Biosciences, he served as vice president of research at Sunesis Pharmaceuticals, Inc. from January 2000 to 2008, where he oversaw drug discovery, translational research and manufacturing functions. Prior to Sunesis Pharmaceuticals, Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals, Inc. Before joining Axys, Dr. McDowell was a senior scientist at Genentech Inc., where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peerreviewed manuscripts and is an inventor on more than 20 issued U.S. patents since 2012.
| Age | 59 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 650 741-0900 |
| Web | www.myokardia.com |
MyoKardia Management Efficiency
The company has return on total asset (ROA) of (23.07) % which means that it has lost $23.07 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (42.7) %, meaning that it created substantial loss on money invested by shareholders. MyoKardia's management efficiency ratios could be used to measure how well MyoKardia manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 51.61 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. MyoKardia has a current ratio of 17.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist MyoKardia until it has trouble settling it off, either with new capital or with free cash flow. So, MyoKardia's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MyoKardia sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MyoKardia to invest in growth at high rates of return. When we think about MyoKardia's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 5 records | SVP Age | ||
| John Mulleady | Dave Busters Entertainment | 63 | |
| John Jakubek | Dine Brands Global | 63 | |
| Jay Tobin | Dave Busters Entertainment | 59 | |
| Kevin Bachus | Dave Busters Entertainment | 49 | |
| Scott Kriss | The Wendys Co | 46 | |
Management Performance
| Return On Equity | -42.7 | |||
| Return On Asset | -23.07 |
MyoKardia Leadership Team
Elected by the shareholders, the MyoKardia's board of directors comprises two types of representatives: MyoKardia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MyoKardia. The board's role is to monitor MyoKardia's management team and ensure that shareholders' interests are well served. MyoKardia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MyoKardia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Topol, Independent Director | ||
| Sunil Agarwal, Independent Director | ||
| Christine MD, Co-Founder | ||
| Taylor Harris, CFO | ||
| Mark Perry, Independent Director | ||
| June Lee, COO | ||
| Cynthia Ladd, General Counsel | ||
| William Fairey, Executive Vice President and Chief Commercial Officer | ||
| Wendy Yarno, Independent Director | ||
| Kevin Starr, Director | ||
| Jake Bauer, Vice President - Business Development and Business Operations | ||
| Joseph Lambing, Senior Vice President - Nonclinical and Pharmaceutical Development | ||
| Steven Chan, Vice President Corporate Controller | ||
| Mary Cranston, Director | ||
| Katherine Bowdish, Director | ||
| Robert McDowell, Sr. VP of Drug Discovery | ||
| David Meeker, Independent Director | ||
| Marc Semigran, Chief Medical Officer | ||
| Leslie Leinwand, Co-Founder | ||
| Tassos Gianakakos, CEO and President and Director | ||
| Charles Homcy, Director | ||
| Jonathan Fox, Chief Medical Officer | ||
| Kimberly Popovits, Independent Director |
MyoKardia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MyoKardia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -42.7 | |||
| Return On Asset | -23.07 | |||
| Current Valuation | 11.15 B | |||
| Shares Outstanding | 53.32 M | |||
| Shares Owned By Insiders | 2.22 % | |||
| Shares Owned By Institutions | 94.59 % | |||
| Number Of Shares Shorted | 4.63 M | |||
| Price To Earning | (57.57) X | |||
| Price To Book | 14.19 X | |||
| Price To Sales | 253.61 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards MyoKardia in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, MyoKardia's short interest history, or implied volatility extrapolated from MyoKardia options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in MyoKardia Stock
If you are still planning to invest in MyoKardia check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyoKardia's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |